The Genitourinary Medical Oncology Program focuses on the treatment of testicular cancers (germ cell tumors), bladder cancer, kidney cancer and prostate cancer and works closely with our radiation oncology and urologic colleagues in the multidisciplinary clinics. These multidisciplinary clinics meet weekly to evaluate, discuss and render a comprehensive treatment approach for patients with genitourinary cancers. The medical oncologists in this program are experts in all stages of genitourinary cancers and have access to a wide range of therapies including dendritic cell based vaccine (Provenge), high dose Interleukin -2, and multiple new investigational drugs (research studies).
Wm. Kevin Kelly, DO, leads the program and has an extensive experience developing novel agents for genitourinary cancers from the bench to the bedside. He currently conducts multiple national and international studies. His research interest includes developing less toxic therapies for patients and developing methods to individualize treatment for patients.
Jianqing Lin, MD, focuses on novel treatment modalities for prostate cancer in different stages including high risk localized disease, rising prostate specific antigen after surgery or radiation therapy, and advanced prostate cancer. Dr. Lin is also the director of the only Philadelphia area high dose Interleukin-2 (IL-2) program for metastatic kidney cancer and melanoma.
Jean Hoffman-Censits, MD, is the director of bladder cancer research and she focuses on developing less toxic and individualized treatments for patients with locally advanced bladder cancer. She has also taken a lead role in developing a regional Bladder Cancer Consortium to screen new agents for the treatment of bladder cancer.
Gwen Salkind, RN works closely with the physicians and they have expertise in assessing and managing treatment related side effects of therapies and medical problems associated with genitourinary tumors.